“Nigeria Secures Breakthrough Twice Yearly HIV Prevention Injection to Strengthen National Fight Against AIDS”

“Nigeria Secures Breakthrough Twice Yearly HIV Prevention Injection to Strengthen National Fight Against AIDS”

Nigeria has received its first supply of Lenacapavir, a long acting HIV prevention injection administered twice a year, marking a significant milestone in the country’s efforts to expand prevention choices and accelerate progress toward ending the HIV epidemic.
Health authorities say the introduction of Lenacapavir represents a major advancement in HIV prevention, particularly for populations facing challenges with daily oral pre exposure prophylaxis (PrEP). The injectable treatment, developed as a long acting antiretroviral option, offers sustained protection against HIV infection through just two doses annually, potentially improving adherence and widening access to prevention services.
Public health experts note that Nigeria carries one of the highest HIV burdens globally, with millions of people living with the virus despite years of intervention programs. The arrival of long acting prevention tools is therefore seen as a strategic step toward reducing new infections, especially among young people, women, and key vulnerable populations who may struggle with consistent daily medication routines.
According to officials involved in the rollout, Lenacapavir will initially be introduced through controlled implementation programs integrated into existing national HIV prevention strategies. The initiative aligns with Nigeria’s broader commitment to achieving global targets aimed at ending AIDS as a public health threat by 2030. Health partners emphasize that the injection will complement not replace existing prevention measures such as condoms, testing campaigns, counseling services, and oral PrEP.
Global health agencies have described long acting HIV prevention technologies as a “game changer” capable of reshaping prevention models across Africa, where structural barriers, stigma, and healthcare access gaps often hinder consistent treatment adherence. Analysts say Nigeria’s adoption signals growing momentum across the continent toward innovative, patient-centered healthcare solutions.
However, experts also caution that success will depend on equitable distribution, sustained funding, community awareness, and strong healthcare infrastructure to ensure the injection reaches those most at risk. Civil society organizations are urging continued investment in education and stigma reduction to maximize the impact of the new prevention option.
The introduction of Lenacapavir comes amid renewed global focus on prevention innovation, with African countries increasingly positioned at the forefront of clinical implementation and public health deployment of next generation HIV tools.